These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9162677)

  • 1. [Lipid factors and evolution of the atherosclerotic plaque: review of recent trials].
    Scardi S
    G Ital Cardiol; 1996 Dec; 26(12):1481-93. PubMed ID: 9162677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The relationship between clinical events and the angiographic lesions in coronary atherosclerosis. Hypolipemic treatment and plaque stabilization].
    Castro Beiras A; Vázquez Rodríguez JM; Muñiz J; Calviño R; Vázquez González N; Juane R
    Rev Esp Cardiol; 1995; 48 Suppl 5():23-30. PubMed ID: 7494936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease.
    Brown BG; Zhao XQ; Sacco DE; Albers JJ
    Circulation; 1993 Jun; 87(6):1781-91. PubMed ID: 8504494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atherosclerosis regression, plaque disruption, and cardiovascular events: a rationale for lipid lowering in coronary artery disease.
    Brown BG; Zhao XQ; Sacco DE; Albers JJ
    Annu Rev Med; 1993; 44():365-76. PubMed ID: 8476257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Can drugs, especially calcium antagonists, bring about regression of atherosclerosis, especially coronary sclerosis?].
    Lichtlen PR
    Schweiz Med Wochenschr; 1991 Dec; 121(49):1807-12. PubMed ID: 1754861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arteriographic view of treatment to achieve regression of coronary atherosclerosis and to prevent plaque disruption and clinical cardiovascular events.
    Brown BG; Zhao XQ; Sacco DE; Albers JJ
    Br Heart J; 1993 Jan; 69(1 Suppl):S48-53. PubMed ID: 8427765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravascular Ultrasound Studies of Plaque Progression and Regression: Impact of Lipid-Modifying Therapies.
    Shishikura D; Honda S; Andrews J; Nicholls SJ
    Cardiol Clin; 2018 May; 36(2):329-334. PubMed ID: 29609762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies.
    Kreisberg RA; Oberman A
    J Clin Endocrinol Metab; 2002 Feb; 87(2):423-37. PubMed ID: 11836262
    [No Abstract]   [Full Text] [Related]  

  • 9. Pixel or death: experience from clinical trials assessing lipid lowering therapy.
    Barth JD
    Can J Cardiol; 1995 May; 11 Suppl C():9C-14C. PubMed ID: 7750051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms underlying reduction of clinical events in lipid lowering trials.
    Mancini GB
    Can J Cardiol; 1995 May; 11 Suppl C():15C-17C. PubMed ID: 7750043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of intensive lipid lowering on coronary atheroma and clinical outcome.
    Houslay ES; Sarma J; Uren NG
    Heart; 2007 Feb; 93(2):149-51. PubMed ID: 17035507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary atherosclerosis stabilization: an achievable goal.
    Maher VM
    Atherosclerosis; 1995 Dec; 118 Suppl():S91-101. PubMed ID: 8821469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lowering LDL cholesterol. How much is enough?].
    März W; Grammer TB
    Internist (Berl); 2007 Mar; 48(3):319-26. PubMed ID: 17333056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression of severe atherosclerotic plaque in patients with mild elevation of LDL cholesterol.
    Schaefer S; Hussein H; Gershony GR; Rutledge JC; Kappagoda CT
    J Investig Med; 1997 Dec; 45(9):536-41. PubMed ID: 9444880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression and regression of the atherosclerotic plaque.
    de Feyter PJ; Vos J; Deckers JW
    Eur Heart J; 1995 Aug; 16 Suppl I():26-30. PubMed ID: 8829954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiographic trials of lipid-lowering therapy: an update.
    Mancini GB
    Curr Opin Lipidol; 1995 Dec; 6(6):379-85. PubMed ID: 8750252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plaque stabilization: a mechanism for the beneficial effect of lipid-lowering therapies in angiography studies.
    Waters D
    Prog Cardiovasc Dis; 1994; 37(3):107-20. PubMed ID: 7972848
    [No Abstract]   [Full Text] [Related]  

  • 19. Lipid lowering and coronary risk.
    Gotto AM
    Isr J Med Sci; 1996 Jun; 32(6):355-9. PubMed ID: 8682640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Serum cholesterol during the course of acute coronary events and secondary prevention of coronary heart disease].
    Garrido Sanjuán JA; Pía Iglesias G; Sesma Sánchez P
    An Med Interna; 2001 Sep; 18(9):464-7. PubMed ID: 11715132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.